Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Intermittent Allergic Rhinitis (IAR).

Trial Profile

Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Intermittent Allergic Rhinitis (IAR).

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Desloratadine (Primary)
  • Indications Allergic rhinitis
  • Focus Therapeutic Use
  • Acronyms ACCEPT-1
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Oct 2009 Results published in Allergy.
    • 17 Mar 2009 Primary endpoint 'Total 5 symptom score' has been met.
    • 17 Mar 2009 Results presented at AAAAI
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top